MCID: PRC019
MIFTS: 52

Precocious Puberty

Categories: Endocrine diseases, Genetic diseases, Metabolic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Precocious Puberty

MalaCards integrated aliases for Precocious Puberty:

Name: Precocious Puberty 53 37 29 73
Cryptogenic Sexual Precocity 73
Familial Precocious Puberty 53
Idiopathic Sexual Precocity 53
Puberty Precocious 55
Sexual Precocity 53

Classifications:



External Ids:

KEGG 37 H00937
ICD10 33 E30.1

Summaries for Precocious Puberty

NIH Rare Diseases : 53 Precocious puberty is when a person's sexual and physical traits develop and mature earlier than normal. Normal puberty typically begins between ages 10 and 14 for girls, and ages 12 and 16 for boys. The start of puberty depends on various factors such as family history, nutrition and gender. The cause of precocious puberty is not always known. Some cases of precocious puberty are due to conditions that cause changes in the body's release of hormones. Treatment involves medications that can stop the release of sexual hormones.

MalaCards based summary : Precocious Puberty, also known as cryptogenic sexual precocity, is related to precocious puberty, male-limited and central precocious puberty. An important gene associated with Precocious Puberty is LHCGR (Luteinizing Hormone/Choriogonadotropin Receptor), and among its related pathways/superpathways are Calcium signaling pathway and Neuroactive ligand-receptor interaction. The drugs Leuprolide and Metformin have been mentioned in the context of this disorder. Affiliated tissues include bone, pituitary and testes, and related phenotypes are adipose tissue and endocrine/exocrine gland

Wikipedia : 76 In medicine, precocious puberty is puberty occurring at an unusually early age. In most cases, the... more...

Related Diseases for Precocious Puberty

Diseases in the Precocious Puberty family:

Precocious Puberty, Central, 1 Precocious Puberty, Central, 2
Central Precocious Puberty Secondary Central Precocious Puberty

Diseases related to Precocious Puberty via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 229)
# Related Disease Score Top Affiliating Genes
1 precocious puberty, male-limited 34.2 CYP19A1 LHCGR
2 central precocious puberty 34.0 GNRH1 KISS1 KISS1R MKRN3
3 idiopathic central precocious puberty 33.7 KISS1 KISS1R MKRN3
4 testotoxicosis 33.1 CYP19A1 GNAS LHCGR
5 mccune-albright syndrome 33.0 CYP19A1 GH1 GNAS
6 hypothalamic hamartomas 32.4 GNRH1 KISS1 KISS1R
7 hypogonadotropic hypogonadism 30.6 GNRH1 KISS1 KISS1R
8 fibrous dysplasia 30.4 GH1 GNAS
9 empty sella syndrome 30.4 GH1 GNRH1
10 prader-willi syndrome 30.3 GH1 GNRH1 MKRN3
11 hyperprolactinemia 30.3 GH1 GNRH1
12 craniopharyngioma 30.3 GH1 GNRH1
13 hypogonadism 30.2 GNRH1 KISS1 KISS1R LHCGR
14 adenoma 30.2 CYP21A2 GH1 GNAS LHCGR
15 hyperandrogenism 30.2 CYP19A1 CYP21A2 GNRH1
16 polycystic ovary syndrome 30.2 CYP19A1 CYP21A2 GNRH1
17 leydig cell tumor 30.2 CYP19A1 CYP21A2 LHCGR
18 lipoid congenital adrenal hyperplasia 30.0 CYP19A1 CYP21A2
19 hypothalamic disease 30.0 GH1 GNRH1
20 pseudohermaphroditism 30.0 CYP19A1 LHCGR
21 adrenal rest tumor 30.0 CYP21A2 GNRH1
22 amenorrhea 30.0 GNRH1 LHCGR
23 hypopituitarism 29.8 GH1 GNRH1
24 luteoma 29.8 CYP19A1 CYP21A2
25 sex cord-gonadal stromal tumor 29.8 CYP19A1 GNAS
26 adrenocortical carcinoma, hereditary 29.8 CYP19A1 CYP21A2 GNAS
27 conn's syndrome 29.7 CYP21A2 GH1 GNAS
28 infertility 29.7 CYP19A1 GNRH1 LHCGR
29 gonadal disease 28.9 CYP19A1 GH1 GNRH1 KISS1 KISS1R LHCGR
30 familial male-limited precocious puberty 12.7
31 precocious puberty, central, 2 12.7
32 precocious puberty, central, 1 12.6
33 spastic paraplegia with precocious puberty 12.4
34 hypotonia, seizures, and precocious puberty 12.4
35 secondary central precocious puberty 12.4
36 precocious puberty, gonadotropin-dependent 12.3
37 aromatase excess syndrome 11.7
38 ovarian sex cord tumor with annular tubules 11.5
39 carpenter syndrome 1 11.3
40 pallister-hall syndrome 11.1
41 adrenal hyperplasia, congenital, due to steroid 11-beta-hydroxylase deficiency 11.1
42 mental retardation, x-linked 102 11.1
43 pineal gland cancer 11.1
44 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 11.1
45 polyembryoma 11.1
46 septo-optic dysplasia spectrum 11.1
47 body mass index quantitative trait locus 1 10.5
48 hypothyroidism 10.5
49 arachnoid cysts 10.4
50 neurofibromatosis, type i 10.4

Graphical network of the top 20 diseases related to Precocious Puberty:



Diseases related to Precocious Puberty

Symptoms & Phenotypes for Precocious Puberty

MGI Mouse Phenotypes related to Precocious Puberty:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 9.77 CYP19A1 GNAS KISS1 KISS1R LHCGR
2 endocrine/exocrine gland MP:0005379 9.73 CYP19A1 GNAS GNRH1 KISS1 KISS1R LHCGR
3 digestive/alimentary MP:0005381 9.72 CYP19A1 GNRH1 KISS1 KISS1R LHCGR
4 integument MP:0010771 9.55 CYP19A1 GNAS GNRH1 KISS1 KISS1R
5 liver/biliary system MP:0005370 9.43 CYP19A1 GNAS GNRH1 KISS1 KISS1R LHCGR
6 renal/urinary system MP:0005367 9.1 CYP19A1 GNAS GNRH1 KISS1 KISS1R LHCGR

Drugs & Therapeutics for Precocious Puberty

Drugs for Precocious Puberty (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 64)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Leuprolide Approved, Investigational Phase 4,Phase 3,Early Phase 1 53714-56-0 657181 3911
2
Metformin Approved Phase 4 657-24-9 14219 4091
3 Deslorelin Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 57773-65-6
4 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
5 Triptorelin Pamoate Phase 4,Phase 3,Not Applicable
6 Luteolytic Agents Phase 4,Phase 3,Not Applicable
7 Contraceptive Agents Phase 4,Phase 3,Not Applicable
8 Fertility Agents Phase 4,Phase 3,Early Phase 1,Not Applicable
9 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
10 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
11 Prolactin Release-Inhibiting Factors Phase 4,Phase 2
12 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Hypoglycemic Agents Phase 4
14 Insulin, Globin Zinc Phase 4
15 insulin Phase 4
16 Pharmaceutical Solutions Phase 3,Phase 2
17
Spironolactone Approved Phase 2 52-01-7, 1952-01-7 5833
18
Testolactone Approved, Investigational Phase 2 968-93-4 13769
19
Testosterone Approved, Investigational Phase 2 58-22-0 6013
20
Bicalutamide Approved Phase 2 90357-06-5 2375 56069
21
Anastrozole Approved, Investigational Phase 2 120511-73-1 2187
22
Fulvestrant Approved, Investigational Phase 2 129453-61-8 17756771 104741
23 Androgens Phase 2,Phase 1,Not Applicable
24 Natriuretic Agents Phase 2
25 Diuretics, Potassium Sparing Phase 2
26 diuretics Phase 2
27 Mineralocorticoids Phase 2
28 Mineralocorticoid Receptor Antagonists Phase 2
29 Estrogens Phase 2,Phase 1
30 Aromatase Inhibitors Phase 2,Phase 1
31 Estrogen Antagonists Phase 2,Phase 1
32 Estrogen Receptor Antagonists Phase 2,Phase 1
33 Steroid Synthesis Inhibitors Phase 2,Phase 1
34 Androgen Antagonists Phase 2
35 Bone Density Conservation Agents Phase 1, Phase 2
36 Calcium, Dietary Phase 1, Phase 2
37
Oxandrolone Approved, Investigational Phase 1 53-39-4 5878
38
Letrozole Approved, Investigational Phase 1 112809-51-5 3902
39 Anabolic Agents Phase 1
40
Ganirelix Approved Early Phase 1 123246-29-7, 124904-93-4 25081094
41
Zinc Approved, Investigational 7440-66-6
42
Histamine Approved, Investigational 51-45-6, 75614-87-8 774
43
Dexamethasone acetate Approved, Investigational, Vet_approved Not Applicable 1177-87-3
44
Dexamethasone Approved, Investigational, Vet_approved Not Applicable 50-02-2 5743
45
Racepinephrine Approved 329-65-7 838
46
Epinephrine Approved, Vet_approved 51-43-4 5816
47
Menotropins Approved Not Applicable 61489-71-2, 9002-68-0 5360545
48 Liver Extracts Not Applicable
49 Follicle Stimulating Hormone Early Phase 1
50
Histamine Phosphate 51-74-1 65513

Interventional clinical trials:

(show top 50) (show all 54)
# Name Status NCT ID Phase Drugs
1 Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children Unknown status NCT00438217 Phase 4 Triptorelin (GnRH agonists);Leuprolide (GnRH agonists)
2 Analysis of Body Mass Index in Central Precocious Puberty Patients Treated With Leuprolide Acetate Unknown status NCT02974270 Phase 4 Leuprolide
3 Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in Girls Unknown status NCT01278290 Phase 4 Triptorelin acetate and Gonadorelin acetate;Gonadorelin acetate and Triptorelin acetate
4 Study of Comprehensive Diagnosis and Treatment for Children Precocious Puberty Completed NCT02920515 Phase 4 Triptorlin or Leuprorelin;Zhibo dihuang pills;Dabu ying pills
5 The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty Completed NCT01634321 Phase 4 Luphere depot 3.75mg(Leuprolide acetate 3.75mg)
6 A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Patients Completed NCT02427958 Phase 4 Leuprorelin
7 Understanding Experimentally Induced Hot Flushes Completed NCT00455689 Phase 4 Leuprolide acetate
8 The Health Influences of Puberty (HIP) Study Completed NCT01775813 Phase 4 Metformin
9 Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty Recruiting NCT03316482 Phase 4 Leuplin DPS 11.25mg
10 A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height Active, not recruiting NCT00840944 Phase 4 somatropin;triptorelin
11 Pharmacokinetic Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty Completed NCT02452931 Phase 3 Leuprolide Acetate 45 mg
12 Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty Completed NCT01467882 Phase 3 Triptorelin
13 Histrelin Subcutaneous Implant in Children With Central Precocious Puberty Completed NCT00779103 Phase 3 Histrelin Subcutaneous Implant
14 Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study Completed NCT00909844 Phase 3 Triptorelin (I.N.N.)
15 Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty Completed NCT00564850 Phase 3 Triptorelin pamoate 11.25mg (Decapeptyl® SR)
16 Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty Completed NCT00667446 Phase 3 Leuprolide Acetate 3 Month Depot
17 Study of Lupron Depot In The Treatment of Central Precocious Puberty Completed NCT00660010 Phase 3 Lupron (leuprolide acetate)
18 A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty Completed NCT00635817 Phase 3 Leuprolide acetate 11.25 mg;Leuprolide acetate 30 mg
19 A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Formulation in Children With Central Precocious Puberty (CPP) Recruiting NCT03695237 Phase 3 Leuprolide Acetate (LA)
20 Severe Decrease of Growth Velocity in Children With Anorexia Nervosa.Therapeutic Trial of Growth Hormone Active, not recruiting NCT01626833 Phase 2, Phase 3 SOMATROPINE* : Norditropine® simplexx®
21 Treatment of Boys With Precocious Puberty Completed NCT00001202 Phase 2 Spironolactone;Testolactone;Deslorelin
22 Testolactone for the Treatment of Girls With LHRH Resistant Precocious Puberty Completed NCT00001181 Phase 2 Testolactone
23 Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis] Completed NCT00094328 Phase 2 Bicalutamide;Anastrozole
24 Encouraging Calcium Absorption and Bone Formation During Early Puberty Completed NCT00022867 Phase 1, Phase 2 Nondigestible oligosaccharide (NDO)
25 Arimidex in McCune Albright Syndrome Completed NCT00055302 Phase 2 Arimidex 1 mg
26 Study of Luteinizing Hormone-Releasing Hormone Analog (LHRHa) in Pubertal Patients With Extreme Short Stature Completed NCT00001190 Phase 2 Deslorelin
27 Faslodex in McCune Albright Syndrome Active, not recruiting NCT00278915 Phase 2 Fulvestrant
28 Pilot Study of the Safety and Efficacy of Oxandrolone in the Prevention and Treatment of Malnutrition in Infants Unknown status NCT01048632 Phase 1 Oxandrolone
29 Effects of Letrozole on Precocious Puberty Due to McCune Albright Syndrome Completed NCT00006174 Phase 1 Letrozole
30 First-Voided Urinary LH vs. GnRH-stimulation in Differentiating Slowly- From Rapidly Progressive-Precocious Puberty Unknown status NCT01800565 Not Applicable
31 Follow-up of Girls With Premature Thelarche and Precocious Puberty Unknown status NCT01944475
32 Clinical Trial of Experienced Chinese Herbal Formulas on Different Types of Precocious Puberty Unknown status NCT02650141 Not Applicable ziyinxiehuo Granules;zishenqinggan Granules
33 Long-term Outcome of GnRH Analogues Treatment of Children With Idiopathic Central Precocious Puberty Unknown status NCT02790112 Not Applicable
34 LH Response to GnRH Test in Prepubescent Girls Under 6 Years Unknown status NCT01944488 Not Applicable GnRH agonist
35 Ultrasound Evaluation of Bone Age in Healthy Children Unknown status NCT01980693 Not Applicable
36 Psychosocial Impact of Early Puberty in Girls Aged 6 to 8 Years Completed NCT01679925
37 Purification of Testis-Stimulating Factor in Precocious Puberty Completed NCT00004344 leuprolide;testosterone
38 A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty (CPP) Among Chinese Participants Completed NCT02993926 Leuprorelin
39 The Effect of Medical Clown on the Pain and Anxiety Perception During LRH Analog Treatment or GH Provocation Test Completed NCT02199587 Not Applicable
40 Follicle-Stimulating Hormone (FSH) and the Onset of Puberty Completed NCT00734279 Early Phase 1 Leuprolide Acetate - Early Puberty Leuprolide Visit;Ganirelix - Early Puberty Ganirelix Visit;Ganirelix - Delayed Puberty Ganirelix Visit;Leuprolide Acetate- Delayed Puberty Leuprolide Visit
41 Study of Gonadotropin-Releasing Hormone Pulse Frequency in Sexual Maturation and in the Menstrual Cycle Completed NCT00004335
42 Exercise in Insulin-Resistant Minority Adolescents Completed NCT00345436
43 Histamine Responsiveness in McCune-Albright Syndrome Completed NCT00318097
44 The Effect of Decaffeinated Green Tea Polyphenol Intake on the Risk of Precocious Puberty Among Obese Girls Recruiting NCT03628937 Not Applicable
45 Association Between Soy Based Formula in Infancy and Puberty Recruiting NCT02908971
46 Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome Recruiting NCT00001727
47 Inherited Reproductive Disorders Recruiting NCT01500447
48 Ovarian Contribution to Androgen Production in Adolescent Girls Recruiting NCT01421810 Not Applicable Dexamethasone;rhCG
49 The Genetic Investigation of Reproductive Disorders (Including Kallmann Syndrome) Recruiting NCT01601171
50 Effect of a GnRH Injection on Ghrelin Concentrations in Girls With Suspected Premature Puberty Active, not recruiting NCT02431416 Not Applicable Gonadotropin releasing hormone (GnRH);Sodium Chloride

Search NIH Clinical Center for Precocious Puberty

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Precocious Puberty

Genetic tests related to Precocious Puberty:

# Genetic test Affiliating Genes
1 Precocious Puberty 29

Anatomical Context for Precocious Puberty

MalaCards organs/tissues related to Precocious Puberty:

41
Bone, Pituitary, Testes, Brain, Ovary, Pineal, Testis

Publications for Precocious Puberty

Articles related to Precocious Puberty:

(show top 50) (show all 1152)
# Title Authors Year
1
Hydroxymethylation of protein-encoding genes in the testes involved in precocious puberty of Eriocheir sinensis. ( 30315924 )
2019
2
CENTRAL PRECOCIOUS PUBERTY CAUSED BY A HETEROZYGOUS DELETION IN THE MKRN3 PROMOTER REGION. ( 29763903 )
2018
3
Central precocious puberty in a case of late-diagnosed familial testotoxicosis and long-term treatment monitoring. ( 29858851 )
2018
4
Herbal medicine for idiopathic central precocious puberty: A protocol for a systematic review of controlled trials. ( 29595688 )
2018
5
Gonadotropin-Releasing Hormone (GnRHa) Therapy for Central Precocious Puberty (CPP): Review of Nuances in Assessment of Height, Hormonal Suppression, Psychosocial Issues, and Weight Gain, with Patient Examples. ( 29806750 )
2018
6
A Case of a Girl with Arnold-Chiari Type 1 Malformation with Precocious Puberty. ( 29383213 )
2018
7
Subnormal Growth Velocity And Related Factors During GnRH Analog Therapy For Idiopathic Central Precocious Puberty. ( 29687783 )
2018
8
Investigation of <i>MKRN3</i> mutation in patients with familial central precocious puberty. ( 29537379 )
2018
9
Evaluation of characteristics of the craniofacial complex and dental maturity in girls with central precocious puberty. ( 29708396 )
2018
10
The prevalence of brain abnormalities in boys with central precocious puberty may be overestimated. ( 29614125 )
2018
11
Analysis of the PvuII and XbaI polymorphisms in the estrogen receptor alpha gene in girls with central precocious puberty: a pilot study. ( 29801469 )
2018
12
LHCGR Gene Analysis in Girls with Non-Classic Central Precocious Puberty. ( 29506309 )
2018
13
Review and evaluation of patient-centered psychosocial assessments for children with central precocious puberty or early puberty. ( 29649000 )
2018
14
Prevalence of cranial MRI findings in girls with central precocious puberty: a systematic review and meta-analysis. ( 29902155 )
2018
15
Etiological trends in male central precocious puberty. ( 29969878 )
2018
16
Peripheral Precocious Puberty Caused by Human Chorionic Gonadotropin Producing Pineal Gland Tumor. ( 29629701 )
2018
17
Malocclusion and maxillofacial characteristics of young girls having precocious puberty. ( 29926997 )
2018
18
Predictors of bone maturation, growth rate and adult height in children with central precocious puberty treated with depot leuprolide acetate. ( 29750651 )
2018
19
Longitudinal follow-up to near final height of auxological changes in girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analog and grouped by pretreatment body mass index level. ( 29609441 )
2018
20
Visceral fat thickness and its associations with pubertal and metabolic parameters among girls with precocious puberty. ( 29969879 )
2018
21
A case of Riley Ruvalcaba syndrome with a novel PTEN mutation accompanied by diffuse testicular microlithiasis and precocious puberty. ( 29194042 )
2018
22
Presentation of central precocious puberty in two patients with Tay-Sachs disease. ( 29943104 )
2018
23
Triptorelin depot for the treatment of children 2 years and older with central precocious puberty. ( 29957076 )
2018
24
Central precocious puberty in Boston boys: A 10-year single center experience. ( 29949619 )
2018
25
Triptorelin (Triptodur) for central precocious puberty. ( 29294465 )
2018
26
Association between bisphenol a exposure and idiopathic central precocious puberty (ICPP) among school-aged girls in Shanghai, China. ( 29650233 )
2018
27
Adult height in patients with familial male-limited precocious puberty and the role of an aromatase inhibitor in patient management. ( 29654692 )
2018
28
The usefulness of circulating levels of leptin, kisspeptin, and neurokinin B in obese girls with precocious puberty. ( 29303010 )
2018
29
Anxiety, Self-esteem and Body Image in Girls with Precocious Puberty. ( 30286845 )
2018
30
Comparison of two bone markers with growth evolution in 74 girls with central precocious puberty. ( 29986677 )
2018
31
Serum levels of LH, IGF-1 and leptin in girls with idiopathic central precocious puberty (ICPP) and the correlations with the development of ICPP. ( 30037185 )
2018
32
Toward More Targeted and Cost-Effective Gonadotropin-Releasing Hormone Analog Treatment in Girls with Central Precocious Puberty. ( 30048994 )
2018
33
Applicability of a novel mathematical model for the prediction of adult height and age at menarche in girls with idiopathic central precocious puberty. ( 30066730 )
2018
34
The clinical effects of gonadotropin-releasing hormone agonists for the treatment of children patients with central precocious puberty. ( 30070338 )
2018
35
Central precocious puberty: From genetics to treatment. ( 30086862 )
2018
36
Serum Osteocalcin Levels in Girls with Central Precocious Puberty: Relation to the Onset of Puberty. ( 30089739 )
2018
37
Increased final adult height by gonadotropin-releasing hormone agonist in girls with idiopathic central precocious puberty. ( 30133462 )
2018
38
Central Precocious Puberty in a Child With Metachromatic Leukodystrophy. ( 30197627 )
2018
39
Associations among IGF-1, IGF2, IGF-1R, IGF-2R, IGFBP-3, insulin genetic polymorphisms and central precocious puberty in girls. ( 30249230 )
2018
40
MKRN3 Levels in Girls with Central Precocious Puberty during GnRHa Treatment: A Longitudinal Study. ( 30269125 )
2018
41
Resistin levels are not associated with obesity in central precocious puberty. ( 30273692 )
2018
42
A mathematical model for predicting the adult height of girls with idiopathic central precocious puberty: A European validation. ( 30300409 )
2018
43
High prevalence of syndromic disorders in patients with non-isolated central precocious puberty. ( 30324796 )
2018
44
Arterial Spin Labeling and Central Precocious Puberty. ( 30397727 )
2018
45
Methylome profiling of healthy and central precocious puberty girls. ( 30466473 )
2018
46
Prevalence of Pathological Brain Lesions in Girls with Central Precocious Puberty: Possible Overestimation? ( 30546283 )
2018
47
Serum inhibin B concentration as a predictor of age at first menstruation in girls with idiopathic central precocious puberty. ( 30550563 )
2018
48
A Case of Familial Male-Limited Precocious Puberty in a Child With Klinefelter Syndrome. ( 30283825 )
2018
49
Management of precocious puberty in girls with McCune-Albright syndrome using letrozole. ( 30475223 )
2018
50
Peculiarities of Precocious Puberty in Boys and Girls With McCune-Albright Syndrome. ( 29988390 )
2018

Variations for Precocious Puberty

Expression for Precocious Puberty

Search GEO for disease gene expression data for Precocious Puberty.

Pathways for Precocious Puberty

Pathways related to Precocious Puberty according to KEGG:

37
# Name Kegg Source Accession
1 Calcium signaling pathway hsa04020
2 Neuroactive ligand-receptor interaction hsa04080
3 GnRH signaling pathway hsa04912

GO Terms for Precocious Puberty

Biological processes related to Precocious Puberty according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 steroid biosynthetic process GO:0006694 9.32 CYP19A1 CYP21A2
2 cognition GO:0050890 9.26 GNAS LHCGR
3 activation of adenylate cyclase activity GO:0007190 9.16 GNAS LHCGR
4 G protein-coupled receptor signaling pathway GO:0007186 9.02 GNAS GNRH1 KISS1 KISS1R LHCGR
5 sterol metabolic process GO:0016125 8.96 CYP19A1 CYP21A2

Molecular functions related to Precocious Puberty according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled peptide receptor activity GO:0008528 8.96 KISS1R LHCGR
2 steroid hydroxylase activity GO:0008395 8.62 CYP19A1 CYP21A2

Sources for Precocious Puberty

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....